A Study of the Safety and Efficacy of Tofimilast in Adult Asthmatics
Public ClinicalTrials.gov record NCT00150397. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Six-Week Study Of The Efficacy And Safety Of Tofimilast Dry Powder For Inhalation In Adults With Persistent Asthma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an initial proof of concept, phase to study to assess the safety and efficacy tofimilast for the chronic maintenance treatment of adults with persistent asthma
Study identification
- NCT ID
- NCT00150397
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 112 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2005
- Primary completion
- Oct 31, 2005
- Completion
- Oct 31, 2005
- Last update posted
- Jun 7, 2012
2005
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Encinitas | California | 92024 | — |
| Pfizer Investigational Site | Riverside | California | 92506 | — |
| Pfizer Investigational Site | DeLand | Florida | 32720 | — |
| Pfizer Investigational Site | Atlanta | Georgia | 30281 | — |
| Pfizer Investigational Site | Normal | Illinois | 61761 | — |
| Pfizer Investigational Site | Madisonville | Kentucky | 42431 | — |
| Pfizer Investigational Site | North Dartmouth | Massachusetts | 02747 | — |
| Pfizer Investigational Site | Springfield | Massachusetts | 01107 | — |
| Pfizer Investigational Site | Minneapolis | Minnesota | 55402 | — |
| Pfizer Investigational Site | Skillman | New Jersey | 08558 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45241 | — |
| Pfizer Investigational Site | Lincoln | Rhode Island | 02865 | — |
| Pfizer Investigational Site | Kingsport | Tennessee | 37660 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37203 | — |
| Pfizer Investigational Site | Dallas | Texas | 75231 | — |
| Pfizer Investigational Site | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00150397, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 7, 2012 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00150397 live on ClinicalTrials.gov.